Newly Diagnosed H3-mutated Glioma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Newly Diagnosed H3-mutated Glioma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT06161974

Study of Olutasidenib and Temozolomide in HGG

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade…

United States60 participantsStarted 2025-03

Treatment: Olutasidenib + TMZ

All recent trials (2 shown)

Active — Not RecruitingPhase 1

NCT04808245

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas

The study "A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas - (INTERCEPT H3)" is a…

Germany15 participantsStarted 2023-02-15

Treatment: Tecentriq 1200 MG in 20 ML Injection, H3K27M peptide vaccine